What are the prescription patterns of DOACs versus warfarin in patients with nonvalvular atrial fibrillation?
Despite increasing overall DOAC use for nonvalvular AF, patients with high thromboembolic risk (CHA2DS2-VASc ≥3) are paradoxically prescribed DOACs less often than warfarin.
Prescription rate of DOACs for nonvalvular AF has increased significantly, with apixaban being the most commonly used agent. Patients with higher CHA2DS2-VASc score (≥3) are prescribed DOACs less often than warfarin. The reason for this discrepancy is unclear. Given the favorable risk-benefit profile of DOACs, further studies are needed to identify factors that determine anticoagulant selection in patients with AF with high thromboembolic risk.
Kattoor et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: